• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Acadia Pharmaceuticals Set to Join S&P SmallCap 600

    12/30/24 5:37:00 PM ET
    $ACAD
    $IBTX
    $SPGI
    $SSB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Banks
    Finance
    Get the next $ACAD alert in real time by email

    NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE:SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions.

    Following is a summary of the change that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    Jan 3, 2025

    S&P SmallCap 600

    Addition

    Acadia Pharmaceuticals

    ACAD

    Health Care

    Jan 3, 2025

    S&P SmallCap 600

    Deletion

    Independent Bank Group

    IBTX

    Financials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com 

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com. 

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected] 

    Media Inquiries

    [email protected] 

    Cision View original content:https://www.prnewswire.com/news-releases/acadia-pharmaceuticals-set-to-join-sp-smallcap-600-302340435.html

    SOURCE S&P Dow Jones Indices

    Get the next $ACAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACAD
    $IBTX
    $SPGI
    $SSB

    CompanyDatePrice TargetRatingAnalyst
    SouthState Corporation
    $SSB
    5/13/2025$106.00Buy
    Truist
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    SouthState Corporation
    $SSB
    4/2/2025$120.00 → $115.00Outperform → Strong Buy
    Raymond James
    SouthState Corporation
    $SSB
    4/1/2025$120.00Overweight
    Barclays
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/11/2025$22.00Hold
    Deutsche Bank
    SouthState Corporation
    $SSB
    1/27/2025$106.00 → $128.00Neutral → Buy
    Citigroup
    ACADIA Pharmaceuticals Inc.
    $ACAD
    1/3/2025$23.00 → $20.00Buy → Neutral
    Guggenheim
    More analyst ratings

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Client Officer Moore Sally sold $255,148 worth of shares (500 units at $510.43), decreasing direct ownership by 9% to 5,131 units (SEC Form 4)

      4 - S&P Global Inc. (0000064040) (Issuer)

      5/7/25 5:33:08 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • EVP, Chief Legal Officer Kemps Steven J sold $1,017,640 worth of shares (2,000 units at $508.82), decreasing direct ownership by 22% to 7,249 units (SEC Form 4)

      4 - S&P Global Inc. (0000064040) (Issuer)

      5/7/25 5:32:23 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • Director Page G Ruffner Jr was granted 295 shares, increasing direct ownership by 0.37% to 79,477 units (SEC Form 4)

      4 - SouthState Corp (0000764038) (Issuer)

      5/6/25 12:32:22 PM ET
      $SSB
      Major Banks
      Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

      Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), Acadia's drug for the treatment of Parkinson's Disease Psychosis. In today's order, the Court ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New Drug Application) filers. "We are very pleased with today's decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038," said Catherine Owen Adams, Chief Executive Officer

      5/16/25 1:43:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • S&P Global to Present at Bernstein's 41st Annual Strategic Decisions Conference on May 29, 2025

      Session will be Webcast NEW YORK, May 13, 2025 /PRNewswire/ -- Martina Cheung, President and Chief Executive Officer of S&P Global (NYSE:SPGI), will participate in Bernstein's 41st Annual Strategic Decisions Conference on May 29, 2025 in New York, New York. Ms. Cheung is scheduled to speak from 11:00 a.m. to 11:50 a.m. (Eastern Daylight Time). The "fireside chat" will be webcast and may include forward-looking information. Webcast Instructions: Live and ReplayThe webcast (audio-only) will be available live and in replay through the Company's Investor Relations website http://investor.spglobal.com/Investor-Presentations (please copy and paste URL into web browser). The webcast replay will be

      5/13/25 4:00:00 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • TARIFFS BITE: NORTH AMERICAN AND ASIAN MANUFACTURERS RETRENCH IN APRIL, WITH GLOBAL MATERIAL PURCHASES DOWN AT ACCELERATED PACE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX

      The steep fall in global manufacturers' purchases signals a likely production slowdown in the near future North America factories respond to tariffs by buying less inputs and aggressively stockpilingPurchasing activity by Asian manufacturers at its weakest since Dec. 2023 as demand slumps across the region's key exporting hubsBright spot: Europe's industrial recession is finally coming to an end as spare capacity shrinks furtherCLARK, N.J., May 13, 2025 /PRNewswire/ -- GEP Global Supply Chain Volatility Index — a leading indicator tracking demand conditions, shortages, transportation costs, inventories, and backlogs based on a monthly survey of 27,000 businesses — indicated an accelerated re

      5/13/25 8:17:00 AM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SouthState Corporation

      SC 13G/A - SouthState Corp (0000764038) (Subject)

      11/14/24 1:28:29 PM ET
      $SSB
      Major Banks
      Finance
    • Amendment: SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc.

      SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

      11/14/24 6:48:52 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by SouthState Corporation

      SC 13G - SouthState Corp (0000764038) (Subject)

      2/14/24 10:04:34 AM ET
      $SSB
      Major Banks
      Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by SouthState Corporation

      SCHEDULE 13G - SouthState Corp (0000764038) (Subject)

      5/13/25 12:17:24 PM ET
      $SSB
      Major Banks
      Finance
    • SEC Form 144 filed by S&P Global Inc.

      144 - S&P Global Inc. (0000064040) (Subject)

      5/12/25 4:55:32 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • SEC Form 13F-HR filed by SouthState Corporation

      13F-HR - SouthState Corp (0000764038) (Filer)

      5/12/25 4:26:31 PM ET
      $SSB
      Major Banks
      Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on South State with a new price target

      Truist initiated coverage of South State with a rating of Buy and set a new price target of $106.00

      5/13/25 9:45:06 AM ET
      $SSB
      Major Banks
      Finance
    • BofA Securities resumed coverage on S&P Global with a new price target

      BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $600.00

      4/10/25 8:19:38 AM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • South State upgraded by Raymond James with a new price target

      Raymond James upgraded South State from Outperform to Strong Buy and set a new price target of $115.00 from $120.00 previously

      4/2/25 7:50:45 AM ET
      $SSB
      Major Banks
      Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Financials

    Live finance-specific insights

    See more
    • Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

      - First quarter total revenues of $244.3 million, up 19% year-over-year - First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year - First quarter DAYBUE® (trofinetide) net product sales of $84.6 million, up 11% year-over-year, and up 9.5% in unique patients shipped - Reiterates full year 2025 revenue guidance including DAYBUE net sales of $380 to $405 million and NUPLAZID net sales of $650 to $690 million - Accelerated timing for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome, topline results now expected in early Q4 2025 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the first quarter ended M

      5/7/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • S&P Global Declares Second Quarter Dividend

      NEW YORK, May 6, 2025 /PRNewswire/ -- The Board of Directors of S&P Global (NYSE:SPGI) has approved a cash dividend on the Corporation's common stock for the second quarter of 2025. The dividend of $0.96 is payable on June 11, 2025, to shareholders of record on May 28, 2025. The annualized dividend rate is $3.84 per share. The Company has paid a dividend each year since 1937 and is one of fewer than 30 companies in the S&P 500® that has increased its dividend annually for more than 50 years. About S&P Global: S&P Global (NYSE:SPGI) provides essential intelligence. We enable governments, businesses and individuals with the right data, expertise and connected technology so that they can make

      5/6/25 4:39:00 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • S&P Global Announces Intent to Separate Mobility Segment into Standalone Public Company

      S&P Global Strongly Positioned to Drive Continued Profitable Growth and Value Creation Across Four Core BusinessesS&P Global Mobility to Be an Automotive Data and Technology Leader with Flexibility to Pursue Near- and Long-Term Growth OpportunitiesCompany Separately Reports First Quarter 2025 Results; Conference Call Today at 8:30 a.m. ETNEW YORK, April 29, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced its intent to separate S&P Global Mobility ("Mobility") from S&P Global to drive long-term value creation. The planned separation is expected to result in Mobility becoming a standalone public company.

      4/29/25 7:22:00 AM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

      9/18/23 10:47:05 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

      9/18/23 10:40:05 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DAYBUE issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

      3/13/23 10:37:07 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Froetscher Janet P bought $250,018 worth of shares (2,717 units at $92.02), increasing direct ownership by 138% to 4,689 units (SEC Form 4)

      4 - SouthState Corp (0000764038) (Issuer)

      3/11/25 4:10:14 PM ET
      $SSB
      Major Banks
      Finance
    • Director Smith G Stacy bought $290,160 worth of shares (3,100 units at $93.60), increasing direct ownership by 9% to 36,779 units (SEC Form 4)

      4 - SouthState Corp (0000764038) (Issuer)

      3/6/25 4:49:33 PM ET
      $SSB
      Major Banks
      Finance
    • Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

      4 - S&P Global Inc. (0000064040) (Issuer)

      6/17/24 4:04:40 PM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Leadership Updates

    Live Leadership Updates

    See more
    • Coinbase Global Set to Join S&P 500

      NEW YORK, May 12, 2025 /PRNewswire/ -- Coinbase Global Inc. (NASD: COIN) will replace Discover Financial Services (NYSE:DFS) in the S&P 500 effective prior to the opening of trading on Monday, May 19. S&P 500 constituent Capital One Financial Corp. (NYSE:COF) is acquiring Discover Financial Services in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector May 19, 2025 S&P 500 Addition Coinbase Global COIN Financials May 19, 2025 S&P 500 Deletion Discover Financial Services DFS Financials For m

      5/12/25 6:00:00 PM ET
      $COF
      $COIN
      $DFS
      $SPGI
      Major Banks
      Finance
      Finance: Consumer Services
    • Okta Set to Join S&P MidCap 400

      NEW YORK, April 28, 2025 /PRNewswire/ -- Okta Inc. (NASD: OKTA) will replace Berry Global Group Inc. (NYSE:BERY) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, May 1. S&P 500 constituent Amcor plc (NYSE:AMCR) is acquiring Berry Global Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector May 1, 2025 S&P MidCap 400 Addition Okta OKTA Information Technology May 1, 2025 S&P MidCap 400 Deletion Berry Global Group BERY Materials For more information about S&P Dow Jon

      4/28/25 6:07:00 PM ET
      $AMCR
      $BERY
      $OKTA
      $SPGI
      Miscellaneous manufacturing industries
      Consumer Discretionary
      Plastic Products
      Industrials
    • S&P Global agrees to acquire ORBCOMM's Automatic Identification System business, strengthening its supply chain and maritime offerings

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- S&P Global (NYSE:SPGI) today announced an agreement to acquire the Automatic Identification System (AIS) data services business of ORBCOMM Inc. The AIS business is a leading provider of satellite data services used to track and monitor vessels, enhancing maritime visibility and delivering critical insights that support business intelligence and decision-making for government and commercial clients worldwide. Since 2004, ORBCOMM's AIS vessel tracking technology has incorporated high-quality, proprietary data with satellite and terrestrial based coverage. Its AIS solutions are utilized for diverse applications such as supply chain visibility, mar

      4/24/25 8:05:47 AM ET
      $SPGI
      Finance: Consumer Services
      Finance